证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2023-072 丽珠医药集团股份有限公司关于 注射用醋酸曲普瑞林微球新适应症上市许可申请获受理的公告 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，丽珠医药集团股份有限公司（以下简称"本公司"）及控股子公司上 海丽珠制药有限公司收到国家药品监督管理局核准签发的《受理通知书》（受理 号：CXHS2300072），受理注射用醋酸曲普瑞林微球子宫内膜异位症注册上市 许可的申请。现将有关详情公告如下： 一、受理通知书主要内容 药品通用名称：注射用醋酸曲普瑞林微球 英文名：Triptorelin Acetate Microspheres for Injection 剂型：注射剂 规格：3.75mg（按 C64H82N18O13计） 申请事项：境内生产药品注册上市许可 注册分类：化学药品 2.4 类 受理通知书审批结论：根据《中华人民共和国行政许可法》第三十二条的规 定，经审查，决定予以受理。 二、药品的相关情况 注射用醋酸曲普瑞林微球是本公司自主开发的高端长效微球制剂，已于2023 年5 ...

Financial Performance - The company's operating revenue for the six months ended June 30, 2023, was RMB 6,689.92 million, representing a 6.15% increase compared to the same period last year[15]. - The net profit attributable to shareholders for the same period was RMB 1,227.31 million, reflecting a decrease of 13.96% year-on-year[15]. - The basic earnings per share increased by 11.93% to RMB 1.22 compared to the previous period[16]. - The company reported a net cash flow from operating activities of RMB 1,046.42 million, which is a 4.52% increase from the previous year[15]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2023, representing a 15% year-over-year growth[30]. - The company achieved operating revenue of RMB 6,689.92 million in the first half of 2023, a year-on-year increase of 6.15% compared to RMB 6,302.57 million in the same period last year[43]. - The net profit attributable to shareholders reached RMB 1,134.57 million, reflecting a year-on-year growth of 11.50% from RMB 1,017.55 million[43]. Revenue Breakdown - Revenue from chemical preparations reached RMB 3,480.29 million, accounting for 52.02% of total revenue, with a growth of 26.63%[16]. - The revenue from biological products was RMB 1,781.67 million, showing a growth of 14.26% year-on-year[16]. - The revenue from the raw materials and intermediates segment reached RMB 1,781.67 million, a year-on-year increase of 3.03%, accounting for 26.63% of the total revenue[54]. - The revenue from the Chinese medicine preparation segment reported revenue of RMB 953.85 million, a significant year-on-year growth of 94.42%, representing 14.26% of the total revenue[57]. - The revenue from diagnostic reagents and equipment decreased to RMB 297.99 million, a decline of 13.88%, making up 4.45% of the total revenue[58]. Market Expansion and Strategy - The company is focusing on expanding its market presence and enhancing its product offerings[18]. - Market expansion plans include entering two new international markets by Q4 2023, aiming for a 5% market share in each[30]. - The company actively expanded its international market presence, focusing on product registration in countries such as Pakistan, Indonesia, and Uzbekistan, with 20 product specifications registered in 11 overseas countries/regions[49]. - The company is considering strategic acquisitions to enhance its product portfolio, with a target of completing at least one acquisition by the end of the fiscal year[30]. Research and Development - The company is investing heavily in R&D, with a budget increase of 25% for new drug development initiatives[30]. - The company is enhancing its R&D capabilities and international collaboration to strengthen its competitive edge in various therapeutic areas[63]. - The company is focusing on innovative drugs and high-barrier complex formulations, leveraging its unique advantages in raw materials and formulations integration[64]. - The company is advancing key projects in the field of biological products, including the approval of the recombinant human chorionic gonadotropin injection for overseas registration in Tajikistan and ongoing submissions in other countries[51]. Operational Efficiency - The gross margin improved to 45%, up from 42% in the previous year, reflecting better cost management[30]. - The company has implemented new technologies in production, resulting in a 30% increase in efficiency[30]. - The company is enhancing its production and quality management systems to improve product delivery capabilities and reduce operational costs through lean production initiatives[48]. - The company has implemented measures to improve operational efficiency and safety awareness among employees through training programs[61]. Financial Position and Liabilities - Total assets at the end of the period were RMB 25,726,127,198.95, representing a 3.46% increase from RMB 24,864,825,366.23 at the beginning of the period[36]. - Total liabilities increased by 15.59%, reaching RMB 11,476,301,953.22 compared to RMB 9,928,573,774.51 at the beginning of the period[36]. - The company's asset-liability ratio rose from 39.93% as of December 31, 2022, to 44.61% as of June 30, 2023[94]. - Long-term borrowings increased by 32.81% to RMB 2,622,263,438.94, attributed to new bank loans[93]. Investment and Capital Expenditure - The company has invested RMB 54,850.66 million in the Sichuan Guangda relocation and expansion project, with government subsidies totaling RMB 17,443.17 million received[120]. - The company made significant investments totaling RMB 727,085,150.00 during the reporting period, a 2,323.61% increase compared to the previous period's investment of RMB 30,000,065.77[123]. - The company plans to invest a total of RMB 20,820.90 million in the new product development and industrial upgrading project, with an expected completion date by December 31, 2020[145]. - The company has committed to using the raised funds for various projects, including the development of innovative products and technology platforms, in line with its strategic goals[141]. Compliance and Risk Management - The company has established risk control measures to mitigate market, operational, and legal risks associated with derivatives trading[136]. - The company emphasizes the importance of regulatory compliance and environmental management, increasing investments in environmental protection equipment[195]. - The company is actively monitoring industry policy changes and will strengthen its compliance and operational systems in response to evolving regulations[186]. Future Outlook - The company has provided a positive outlook for the second half of 2023, projecting a revenue growth of 10% to 12%[30]. - The company plans to enhance its R&D efficiency and strengthen its innovative drug and complex formulation platforms in the second half of 2023[176]. - The company aims to deepen its market presence in key disease areas such as autoimmune diseases and respiratory infections through targeted sales management[183].

Financial Performance - In 2022, Livzon Pharmaceutical Group achieved a revenue of RMB 12,629.58 million, representing a year-on-year growth of 4.69%[8] - The net profit attributable to shareholders for 2022 was RMB 1,909.39 million, an increase of 7.53% compared to the previous year[8] - Excluding non-recurring gains and losses, the net profit attributable to shareholders from core operations was RMB 1,880.46 million, reflecting a growth of 15.57% year-on-year[8] - The company reported a total revenue of RMB 12,629.58 million for the year, representing a 4.69% increase compared to the previous year[16] - The net profit attributable to shareholders was RMB 1,909.39 million, reflecting a growth of 7.53% year-on-year[16] - The company achieved a 15.57% increase in cash flow from operating activities, amounting to RMB 2,772.67 million[16] - The basic earnings per share for 2022 was RMB 2.04, a 7.37% increase from RMB 1.90 in 2021[42] - The total amount of public welfare donations made by the company during the reporting period was approximately RMB 9.98 million[12] Business Development and Strategy - Livzon is focusing on innovative drug development in areas such as digestive, mental health, reproductive assistance, and oncology, with a differentiated product pipeline covering the entire R&D cycle[11] - The company aims to strengthen its competitive advantage through digital transformation and improved operational management[7] - Livzon is actively pursuing business development opportunities, including potential mergers and acquisitions to enhance its product portfolio and market presence[31] - The company has expanded its market channels and established an internet digital marketing platform to increase product penetration in the OTC retail market[12] - The company is committed to enhancing its R&D pipeline, particularly in high-barrier complex formulations and innovative drugs, to meet evolving market demands[49] - The company is focusing on enhancing its product competitiveness through digital transformation and improving operational efficiency[57] Research and Development - Livzon has established a Clinical Research Management Center to optimize the management structure of its medical, clinical operations, and registration teams[11] - The company completed the Phase III clinical trial for the Semaglutide injection and submitted supplementary materials for the prostate cancer indication of Triptorelin microspheres[12] - The company has 86 ongoing R&D projects as of the end of 2022, with 1 project in the clinical evaluation stage[106] - The company has made significant progress in the research and development of complex formulations and new drugs in oncology, reproductive health, and autoimmune diseases[61] - The company is focusing on the development of new traditional Chinese medicine projects, with eight new drug research projects currently underway[72] Market Expansion - Livzon's market expansion efforts have led to a 20% increase in user data, with a growing customer base in both domestic and international markets[31] - The company is actively expanding its international business, particularly in markets such as Pakistan, Indonesia, and Uzbekistan[60] - The company has successfully registered 5 chemical preparation products in overseas markets and submitted 6 new registrations as of December 31, 2022[63] - The company is advancing the conditional listing application for its recombinant COVID-19 vaccine, which has been included in the national immunization program and is now used in over 20 provinces[64] Corporate Governance and Social Responsibility - The board proposed a cash dividend of RMB 16.00 per 10 shares for the 2022 fiscal year, pending approval at the annual general meeting[10] - The company is committed to social responsibility by providing precise assistance to chronic and rare disease patients, contributing to health initiatives in rural areas[15] - The company has established a foreign exchange risk management system to mitigate exposure from non-RMB transactions[147] Financial Position and Assets - Total assets as of December 31, 2022, reached RMB 24,864.83 million, an increase of 11.14% from RMB 22,371.92 million at the end of 2021[42] - The company reported a total of 935,552,687 shares outstanding as of the last trading day before disclosure[44] - The company's total assets increased from RMB 22,366,000,000.00 at the end of 2021 to RMB 24,900,000,000.00 at the end of 2022, reflecting a growth of approximately 11.3%[114] - Cash and cash equivalents rose to RMB 10,411,348,410.09, accounting for 41.87% of total assets, up from 40.88% in the previous year[114] Investment and Financial Management - The company has capital commitments of approximately RMB 406.79 million as of December 31, 2022, down from RMB 886.35 million at the end of 2021[142] - The investment amount for the year was RMB 40,000,152.05, representing a significant decrease of 95.49% compared to RMB 886,650,000.00 in the previous year[154] - The company received government subsidies totaling RMB 13,843.17 million for the Sichuan Guangda relocation and expansion project[151] - The financial performance indicates a need for improved management of investment risks, as evidenced by the reported losses[158] Risk Management - The report includes an analysis of potential risks and response strategies for future development[19] - Forward-looking statements in the report are subject to risks and uncertainties, and actual results may differ significantly from these statements[19] - The company emphasizes the importance of not relying on or using such information improperly, as it may lead to investment risks[19]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 麗 珠 醫 藥 集 團 股 份 有 限 公 司 LIVZON PHARMACEUTICAL GROUP INC.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：1513） 2023年第一季度報告 麗珠醫藥集團股份有限公司Livzon Pharmaceutical Group Inc.*（「本公司」或「公司」，連同其附 屬公司，統稱「本集團」）根據香港聯合交易所有限公司證券上市規則第13.09條和第13.10B條以 及香港法例第571章證券及期貨條例第XIVA部內幕消息條文刊發本公告。 本公司及本公司董事會（「董事會」）全體成員保證信息披露的內容真實、準確、完整，沒有虛假 記載、誤導性陳述或重大遺漏。 重要內容提示： 1. 本公司董事會、監事會及董事、監事、高級管理人員保證公司2023年第一季度報告（「本 ...

[0 -> 28] 大家好欢迎参加力珠集团2022年业绩交流会目前所有参会者均处于静音状态现在开始Follow me的声明声明播报完毕后主持人可直接开始发言谢谢本次电话会议仅服务于新业证券客户会议音频及文字记录的内容版权为新业证券所有内容必须经新业证券审核后方可留存 [29 -> 51] 未经允许和授权转载转发此次会议内容均属侵权新义证券将保留追究其法律责任的权利电话会议所有参会人员不得泄露内幕信息以及未公开重要信息涉及外部嘉宾发言的新义证券不保障其发言内容的准确性与完整性 [51 -> 77] 深夜证券不承担外部嘉宾发言内容所引起的任何损失及责任不承担因转载转发引起的任何损失及责任市场有风险投资需谨慎提醒投资者注意投资风险审慎参考会议内容各位投资人上午好欢迎来到力柱集团2022年业绩交流会 [77 -> 105] 我們今天非常榮幸的邀請到公司管理層為我們線上解讀公司2022年的經營情況今天出席的公司領導有公司執行董事、總裁唐陽剛先生副董裁、財務負責人副董裁、董事會秘書楊亮先生研究院院長、化學藥首席科學家與務求公司總經理許堅先生我是興業證券的醫藥分析師黃漢陽 [105 -> 134] 那今天和我一同在线主持的 ...

Financial Performance - The company achieved a revenue of RMB 12,629.58 million for the year 2022, representing a year-on-year growth of 4.69%[9] - The net profit attributable to shareholders for 2022 was RMB 1,909.39 million, an increase of 7.53% compared to the previous year[9] - Excluding non-recurring gains and losses, the net profit attributable to shareholders from core operations was RMB 1,880.46 million, reflecting a growth of 15.57% year-on-year[9] - The company reported a total revenue of RMB 12,629.58 million for the year, representing a year-on-year increase of 4.69%[17] - The net profit attributable to shareholders was RMB 1,909.39 million, reflecting a growth of 7.53% compared to the previous year[17] - The company achieved a net cash flow from operating activities of RMB 2,772.67 million, which is an increase of 15.57% year-on-year[17] - The basic earnings per share for 2022 was RMB 2.04, reflecting a 7.37% increase from RMB 1.90 in 2021[43] - The company's total assets as of December 31, 2022, were RMB 24,864,825.37 thousand, an 11.14% increase from RMB 22,371,915.59 thousand at the end of 2021[43] - The company's total liabilities increased by 23.17% to RMB 9,928,573.77 thousand in 2022, compared to RMB 8,060,890.80 thousand in 2021[43] - The return on equity attributable to shareholders was 13.76% in 2022, up from 13.66% in 2021[43] Research and Development - The company is focusing on innovative drug development in areas such as digestive, mental health, reproductive assistance, and oncology, with a differentiated product pipeline covering the entire R&D cycle[12] - The company has initiated Phase III clinical trials for several new products, including Semaglutide injection and Triptorelin microspheres[15] - Livzon's R&D investment reached 200 million CNY in 2022, accounting for 13% of total revenue, reflecting a strong commitment to innovation and new product development[36] - The company emphasizes research and development as the foundation for sustainable growth, targeting unmet clinical needs and focusing on innovative drugs and complex formulations[50] - The company has 26 ongoing key projects, with 5 in the production application stage and 3 in the clinical approval stage[103] - The number of R&D personnel increased to 973 in 2022, a growth of 3.95% compared to 936 in 2021[108] - The company has 86 ongoing research projects as of the end of 2022, with one project in the clinical evaluation stage[107] - The company is advancing research in dual-specific antibodies and NKT cell therapy, enhancing its R&D capabilities[68] Product Development and Innovation - The recombinant novel coronavirus fusion protein vaccine (Likan) was approved for emergency use in June 2022 and is now included in the national immunization program[12] - The company launched the recombinant humanized anti-IL-6R monoclonal antibody injection (Tocilizumab) in January 2023, enhancing the accessibility of medication for COVID-19 patients[12] - The company has made significant progress in the development of a recombinant COVID-19 vaccine, which was approved for emergency use and is now included in the national immunization program[65] - The company has enhanced its production capabilities by completing the construction of a new formulation workshop to meet market demand for vaccines[65] - The company’s monoclonal antibody injection for rheumatoid arthritis has been approved, contributing to alleviating supply shortages during the pandemic[67] - The company’s first pet formulation product, Pyriproxyfen and Moxidectin drops, was launched in 2022, marking a significant entry into the pet medicine market[69] Market Expansion and Strategy - The company plans to deepen market promotion and leverage digital and intelligent technologies to enhance sustainable development capabilities[15] - Livzon is actively pursuing strategic partnerships and potential acquisitions to bolster its product portfolio and expand its market reach[36] - The company plans to enhance its market presence in Southeast Asia, targeting a 20% increase in market share over the next three years[38] - The company is actively pursuing international market expansion, particularly in countries like Pakistan, Indonesia, and the Philippines[61] - The company is committed to international expansion and innovation-driven business models to enhance its global market presence[50] Corporate Governance and Social Responsibility - The total amount of public welfare donations made by the company during the reporting period was approximately RMB 9.98 million[16] - The company aims to achieve carbon neutrality by 2055 and is actively investing in environmental protection initiatives[16] - The company is committed to providing precise assistance to chronic and rare disease patients, contributing to health initiatives in rural areas[16] - The company received government subsidies amounting to RMB 183,348,565.80, contributing 7.87% to total profit[113] Financial Management and Investments - The company repurchased a total of 1,696,100 A-shares during the reporting period, utilizing a total of RMB 55,925,653.00[78] - The company has capital commitments of approximately RMB 406.79 million as of December 31, 2022, down from RMB 886.35 million at the end of 2021[143] - The investment amount for the year was RMB 40,000,152.05, representing a significant decrease of 95.49% compared to RMB 886,650,000.00 in the previous year[155] - The company is focusing on expanding its market presence through strategic investments in biotechnology and healthcare sectors[156] Risk Management - The report includes an analysis of potential risks and strategies for future development[20] - Forward-looking statements in the report are subject to risks and uncertainties, and actual results may differ significantly from these statements[20] - The company did not experience any changes in accounting policies or significant accounting errors during the reporting period[41]

Financial Performance - The company's operating revenue for Q3 2022 was CNY 3,185,688,204.81, representing a year-on-year increase of 1.66%[2] - Net profit attributable to shareholders for Q3 2022 was CNY 489,254,328.37, reflecting a significant increase of 25.37% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 462,530,618.00, up by 9.01% year-on-year[2] - The company's operating revenue for the first nine months of 2022 was RMB 9,488.25 million, a year-on-year increase of 1.27%[8] - The net profit attributable to shareholders for the first nine months of 2022 was RMB 1,506,800,118.40, compared to RMB 1,452,730,415.78 in the previous year, indicating an increase of about 3.73%[17] - The company's total operating profit for the first nine months of 2022 was RMB 1,872,605,981.76, slightly down from RMB 1,874,923,979.34 in the same period of 2021, indicating a decrease of about 0.12%[17] - The total comprehensive income for the period (January to September 2022) was approximately RMB 1.66 billion, an increase from RMB 1.45 billion in the same period of 2021, representing a growth of about 14.2%[18] Assets and Liabilities - The total assets at the end of the reporting period were CNY 23,569,873,466.33, an increase of 5.35% from the end of the previous year[3] - The total equity attributable to shareholders at the end of the reporting period was CNY 13,432,828,237.84, up by 3.30% from the previous year[3] - The total liabilities increased to RMB 9,058,494,489.03 at the end of the reporting period, compared to RMB 8,060,890,797.20 at the beginning of the year, marking an increase of about 12.35%[16] - The company's total non-current liabilities rose to RMB 2,324,476,858.20, compared to RMB 1,135,822,729.96 at the beginning of the year, reflecting an increase of approximately 104.8%[16] Cash Flow - The company's cash flow from operating activities for the period was CNY 1,847,923,769.75, showing a substantial increase of 41.57% year-on-year[2] - The net cash flow from operating activities rose by 41.57% to RMB 1,847.92 million, driven by increased sales receipts and reduced marketing expenses[9] - The net cash flow from investing activities was negative RMB 769 million, an improvement from negative RMB 1.37 billion in the same period of 2021[19] - The net cash flow from financing activities was negative RMB 757 million, which is an improvement compared to negative RMB 898 million in the previous year[20] Shareholder Information - The company had a total of 67,097 common shareholders at the end of the reporting period[10] - The company has a significant shareholder structure, with Hong Kong Central Clearing (Agent) Limited holding 309,562,240 shares, representing a major portion of the equity[12] - Health元药业集团股份有限公司 holds 221,376,789 shares, indicating its substantial stake in the company[12] Revenue Breakdown - The revenue from chemical products was RMB 5,571.60 million, a decrease of 3.40% year-on-year, with digestive products declining by 11.60%[8] - The revenue from raw materials and intermediates increased by 15.99% to RMB 2,499.26 million, indicating strong demand in this segment[8] Other Comprehensive Income - The company reported a significant increase in other comprehensive income after tax, rising by 163.56% to RMB 100.29 million, mainly due to foreign exchange fluctuations[8] - The company’s other comprehensive income attributable to shareholders of the parent company was RMB 97.61 million, a significant recovery from a loss of RMB 157.51 million in the same period of 2021[18] Research and Development - Research and development expenses for the first nine months of 2022 amounted to RMB 978,746,743.57, up from RMB 786,282,945.23 in the same period last year, reflecting a growth of approximately 24.5%[17] - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[15]

Financial Performance - Livzon Pharmaceutical Group reported a revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[15]. - The company's operating revenue for the current period is RMB 6,302,565,210.60, representing a 1.08% increase compared to the previous period's RMB 6,235,531,036.28[26]. - The total revenue for the reporting period reached RMB 6,239,730,885.56, representing a year-on-year increase of 0.74% compared to RMB 6,193,787,467.88 in the previous period[52]. - Livzon aims to achieve a revenue target of RMB 2.5 billion for the full year 2022, reflecting a growth rate of 12%[15]. - The net profit attributable to shareholders for the first half of 2022 was RMB 300 million, up 10% compared to the same period last year[15]. - Net profit attributable to shareholders for the current period is RMB 1,017,545,790.03, showing a decrease of 4.23% from RMB 1,062,475,917.41 in the previous period[26]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 13.73% to RMB 1,046,423,474.50 from RMB 920,069,483.32[26]. - The net profit of LIZHU PHARMACEUTICAL GROUP CO., LTD. for the first half of 2022 was approximately CNY 292.11 million, with a significant contribution from its subsidiary LIZHU GROUP FUZHOU FUXING PHARMACEUTICAL, which reported a net profit of CNY 266.88 million[110]. Research and Development - Livzon is investing RMB 200 million in R&D for new drug development, focusing on oncology and autoimmune diseases[15]. - The company focuses on R&D innovation, particularly in unmet clinical needs, with a strong emphasis on innovative drugs and complex formulations[31]. - The company is advancing high-barrier complex preparations, with several products in the clinical trial and approval stages, including long-acting microspheres[35]. - The company is committed to enhancing operational management and R&D efficiency to strengthen its competitive advantage in the market[34]. - The company aims to enhance its R&D capabilities by focusing on innovative drugs and complex formulations, aiming to strengthen its product pipeline and attract high-end R&D talent[114]. - The company is actively exploring market expansion opportunities in the health and pharmaceutical industries[90]. - The company has established a clear and rich product R&D pipeline, enhancing its competitive edge in the pharmaceutical industry[47]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia and Europe, targeting a 20% increase in international sales by the end of 2023[15]. - Livzon is exploring potential mergers and acquisitions to enhance its product portfolio and market reach, with a budget of RMB 500 million allocated for this purpose[15]. - The company is actively promoting its products in international markets, including Pakistan, Indonesia, the Philippines, Malaysia, and Uzbekistan, particularly in reproductive assistance and antifungal products[35]. - The company has established strategic partnerships with three international pharmaceutical firms to enhance its research capabilities and market access[15]. - The company is enhancing its international layout and actively pursuing innovative business cooperation models globally[31]. Financial Position and Assets - Total assets at the end of the period reached RMB 22,937,729,133.65, reflecting a 2.53% increase from RMB 22,371,915,590.82 at the beginning of the period[26]. - Total liabilities increased by 11.04% to RMB 8,950,902,250.48 from RMB 8,060,890,797.20[26]. - The company's total equity attributable to shareholders decreased by 1.05% to RMB 12,866,920,066.87 from RMB 13,003,763,631.47[26]. - Cash and cash equivalents at the end of the reporting period amounted to RMB 9,232,850,780.02, accounting for 40.25% of total assets, a decrease of 0.63% compared to the previous year[64]. - The asset-liability ratio increased from 36.03% as of December 31, 2021, to 39.02% as of June 30, 2022[70]. Operational Efficiency - The net cash flow from operating activities surged by 111.34% to RMB 1,426,385,813.18 compared to RMB 674,910,992.08 in the previous period[26]. - Total expenses, including sales, management, R&D, and financial expenses, amounted to RMB 2,717.46 million, a decrease of RMB 99.65 million or 3.54% year-on-year[57]. - The company has established a comprehensive marketing system with nearly 10,000 professional sales personnel covering major medical institutions and pharmacies nationwide[49]. - The quality management system has been continuously improved, ensuring the safety and stability of products, thereby enhancing market competitiveness[50]. Regulatory and Market Challenges - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[15]. - The company faced pricing pressure due to national drug procurement policies, with an average price reduction of 61.71% for 67 exclusive drugs negotiated in 2021[121]. - The company is actively monitoring national medical insurance policies and will enhance post-market clinical and pharmacoeconomic research in response to upcoming negotiations[122]. Corporate Governance and Compliance - The company has adhered to the Corporate Governance Code and the Standard Code as per the Hong Kong Listing Rules from January 1, 2022, to June 30, 2022[175][176]. - The board believes that the company's governance practices align with the requirements of the Corporate Governance Code and there are no discrepancies[174]. - The company has retained the auditing firm, Grant Thornton, for the 2022 fiscal year[185]. - The company has not experienced any significant litigation or arbitration matters during the reporting period[184]. Investment and Funding - The total amount of funds raised by the company through a private placement was RMB 145,782.00 million, with a net amount of RMB 142,030.04 million after deducting issuance costs[100]. - The company has committed to invest RMB 45,000,000 in the development and industrialization upgrade of the Aprazole series innovative products, with 76.69% of the investment completed by December 31, 2024[101]. - The company has not reported any significant investments, acquisitions, or disposals of subsidiaries during the reporting period[112]. - The company has adjusted its fundraising project for the development of monoclonal antibody drugs, reallocating a total of RMB 366 million for various projects, including RMB 143.29 million for a new pharmaceutical project[105]. Employee and Stock Options - The company continues to implement its stock option incentive plan and long-term partnership holding plan for employees[183]. - The total number of stock options held by middle management and key personnel (1,023 individuals) was 4,671,509, with 283,479 options exercised during the period[153]. - The company has approved amendments to the stock option incentive plan, stating that dividends will not adjust the exercise price of stock options[149]. Subsidiary Performance - The subsidiary, Lijun Group, reported a revenue of RMB 4,073.99 million and a net profit of RMB 716.47 million, contributing significantly to the overall financial performance[108]. - The subsidiary Sichuan Guangda reported a revenue of RMB 1,385.08 million and a net profit of RMB 21.14 million, reflecting its operational effectiveness[108].

Revenue and Profit - Revenue for Q1 2022 reached RMB 3,479,027,465.92, an increase of 3.86% compared to RMB 3,349,814,145.87 in the same period last year[2] - Net profit attributable to shareholders was RMB 553,293,797.77, reflecting a growth of 6.47% from RMB 519,651,078.57 year-on-year[2] - Net profit excluding non-recurring items increased by 15.61% to RMB 561,046,433.69 from RMB 485,302,200.16 in the previous year[2] - The company achieved operating revenue of RMB 3,479.03 million, a year-on-year increase of 3.86%[7] - Total profit for the current period was RMB 723,790,862.48, an increase from RMB 703,848,522.76 in the previous period, representing a growth of 2.68%[16] Earnings Per Share - The basic earnings per share for the quarter was RMB 0.59, up 5.36% from RMB 0.56 in the same period last year[2] - The diluted earnings per share increased by 7.27% to RMB 0.59 from RMB 0.55 year-on-year[2] - Basic earnings per share rose to 0.59, up from 0.56 in the previous period, reflecting a growth of 5.36%[17] Cash Flow - Operating cash flow net amount rose significantly by 38.03% to RMB 710,308,938.96 compared to RMB 514,620,182.77 in the same quarter last year[2] - The net cash flow from operating activities was RMB 710,308,938.96, representing a 38.03% increase compared to the previous year[8] - Cash inflow from financing activities totaled approximately ¥1.70 billion, an increase from ¥1.28 billion in the previous period, reflecting a growth of about 33%[19] - Net cash flow from financing activities was approximately ¥353.34 million, a turnaround from a negative cash flow of ¥82.49 million in the previous period[19] - The net increase in cash and cash equivalents was approximately ¥835.52 million, compared to ¥237.35 million in the previous period, representing an increase of about 252%[19] Assets and Liabilities - Total assets at the end of the reporting period were RMB 23,729,888,204.20, a 6.07% increase from RMB 22,371,915,590.82 at the end of the previous year[2] - Total current assets increased to RMB 15,807,296,634.71 from RMB 14,673,096,594.67, representing an increase of approximately 7.7%[14] - Total liabilities increased to RMB 8,799,314,102.16 from RMB 8,060,890,797.20, reflecting a growth of approximately 9.2%[15] - Short-term borrowings decreased by 31.19% to RMB 1,405,807,901.10, primarily due to repayments by subsidiaries[6] - Long-term borrowings increased significantly to RMB 1,626,661,809.48 from RMB 636,780,252.78, indicating a rise of approximately 155.5%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 57,995, including 57,970 A-share shareholders[9] - The top shareholder, Hong Kong Central Clearing Limited, holds 312,934,017 shares, representing 33.35% of the total shares[10] - Health元药业集团股份有限公司 is the second-largest shareholder with 221,376,789 shares, accounting for 23.59%[10] Other Financial Metrics - The company reported a significant increase in right-of-use assets by 52.95% due to new lease agreements signed during the period[6] - Research and development expenses increased to RMB 288,330,797.66, a rise of 24.5% from RMB 231,485,371.64 in the previous period[16] - The company’s financial expenses increased, with interest expenses rising to RMB 23,448,658.85 from RMB 14,068,040.27, indicating a rise of 66.5%[16] - The company reported a decrease in other comprehensive income, with a net amount of RMB -14,442,932.04 compared to RMB -123,910,341.14 in the previous period, showing improvement[17] - The company’s investment income from joint ventures and associates improved significantly to RMB 15,078,700.65, compared to a loss of RMB -3,506,817.44 in the previous period[16]

Financial Performance - The company achieved a revenue of RMB 12,063.86 million in 2021, representing a year-on-year growth of 14.67%[8] - The net profit attributable to shareholders was RMB 1,775.68 million, an increase of 3.54% compared to the previous year[8] - The main business net profit, excluding non-recurring gains and losses, was RMB 1,627.05 million, reflecting a growth of 13.66% year-on-year[8] - The total operating revenue for the year was RMB 12,063.86 million, representing a year-on-year increase of 14.67%[17] - The net profit attributable to shareholders was RMB 1,775.68 million, with a decrease of 9.79% compared to the previous year[17] - The cash flow from operating activities was RMB 1,431.55 million, reflecting a decline of 11.96% year-on-year[17] - The basic earnings per share for the year was RMB 1.90, showing a 3.83% increase from the previous year[18] - The company's total revenue for 2021 reached RMB 12,063.86 million, a year-on-year increase of 14.67% from RMB 10,520.41 million in 2020[50] - Net profit attributable to shareholders for 2021 was RMB 1,775.68 million, reflecting a 3.54% increase compared to RMB 1,714.91 million in the previous year[50] Research and Development - The company has made significant progress in R&D, with the injection of Triptorelin microspheres completing Phase III clinical trials and registration application[10] - The V-01 vaccine, developed in collaboration with the Chinese Academy of Sciences, has shown excellent safety and immunogenicity in Phase I/II trials and is currently undergoing Phase III trials globally[11] - The company is investing RMB 500 million in R&D for new drug development, focusing on oncology and autoimmune diseases[29] - Research and development expenses for the reporting period amounted to approximately RMB 1,523.26 million, an increase of 53.93% year-on-year, accounting for 12.63% of the total operating revenue[45] - The company is focusing on high-barrier complex formulations and innovative drugs, particularly in reproductive assistance, digestive, and oncology fields[45] - The company has 932 research and development personnel as of the end of the reporting period, reflecting a strong commitment to innovation[45] - The company has initiated Phase III clinical trials for a recombinant COVID-19 vaccine in multiple countries, showcasing its commitment to addressing urgent health needs[45] Market Strategy and Expansion - The company plans to accelerate new product development and enhance operational efficiency through digital and intelligent transformation[15] - The company aims to achieve carbon neutrality by 2055 and will increase investment in environmental protection and energy conservation[16] - Livzon plans to expand its market presence in Southeast Asia, targeting a 30% market share in the region by 2025[29] - The company will continue to focus on unmet clinical needs and internationalization efforts to enhance market share[15] - The company is actively seeking international collaboration opportunities and has established a carbon neutrality goal by 2055, incorporating ESG criteria into management assessments[12] - The company is enhancing its product structure by focusing on innovative drugs and high-barrier complex formulations[67] Product Development and Portfolio - The sales revenue from chemical preparations amounted to RMB 7,224.42 million, representing a 33.71% year-on-year growth and accounting for 60.56% of the company's main business revenue[51] - The company has established a comprehensive product cluster covering various therapeutic areas, indicating a diversified product portfolio[44] - The company has developed diagnostic kits for HIV and COVID-19, enhancing its product portfolio[33] - The company has launched two new products in the last quarter, contributing to a 10% increase in sales volume[29] - The company has completed Phase III clinical studies for the injectable Triptorelin microspheres and is progressing with other complex formulations[51] Financial Management and Investments - The company has committed RMB 19.45 million to public welfare donations during the reporting period[16] - The company reported a significant increase in energy costs, which accounted for 6.94% of total operating costs, compared to 7.49% in the previous year[79] - The company has not utilized all the raised funds from its non-public stock issuance as of June 15, 2021[35] - The company has a profit distribution plan to distribute a cash dividend of RMB 13.00 per 10 shares to shareholders[21] - The company has established a strong R&D capability with international standards, focusing on areas such as reproductive assistance, digestion, and oncology[66] Corporate Governance and Compliance - The company has engaged Minsheng Securities as its sponsor for continuous supervision from September 20, 2016, to December 31, 2021[35] - The company has appointed new representatives for continuous supervision due to personnel changes at Minsheng Securities[35] - The company’s financial advisor role is not applicable for the current year[36] - The company’s contact information includes a dedicated board secretary and securities representative for investor relations[30] - The company’s annual report is disclosed on multiple platforms including the Shenzhen Stock Exchange and Hong Kong Stock Exchange[30] Sustainability and ESG Initiatives - The company is actively seeking international collaboration opportunities and has established a carbon neutrality goal by 2055, incorporating ESG criteria into management assessments[12] - The company has introduced ESG assessment indicators into management evaluations to enhance sustainable development efforts[63] - The company is committed to improving its quality management system, ensuring product safety and stability across all business processes[69] Challenges and Risks - The company has reported a significant market risk associated with commodity price fluctuations, necessitating the use of financial derivatives for risk management[156] - The company has faced significant changes in project feasibility due to regulatory adjustments and cost control measures affecting the sales of the "Lijun Group's Limin Hair Injection" project[169] - The company has suspended the development of certain products due to market changes, reallocating funds to enhance capital efficiency[180]